Calaspargase Pegol

Evidence Level: L5

Predicted Indications: 4

Calaspargase Pegol

Pharmacist Assessment Report

Calaspargase pegol: PEGylated asparaginase (asparagine-depleting enzyme) → insomnia

One-Sentence Summary

Calaspargase pegol is a PEGylated asparaginase that depletes circulating asparagine. The TxGNN model predicts it may be effective for insomnia, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction is a model output only.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	insomnia
TxGNN Prediction Score	0.9980
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Calaspargase pegol is a PEGylated form of asparaginase. Asparaginase products break down circulating asparagine, which starves cells that depend on it.

No plausible mechanistic link to insomnia was identified. Insomnia is better understood as a non-specific central nervous system effect seen in the context of chemotherapy regimens, not as a therapeutic target for this drug. The high score of 0.9980 is a model-based output and is not supported by any trial or publication, so it should not be read as evidence of benefit.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02542943	ASPARLAS	Not recorded	Not recorded

Cytotoxicity

Item	Content
Cytotoxicity Classification	Enzyme-based antineoplastic (asparagine-depleting agent), not a conventional DNA-damaging cytotoxic
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions. Asparaginase products are associated with lower synthesis of antithrombin, fibrinogen and other coagulation proteins, so coagulation parameters and liver function are relevant to monitor.
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions: 100 interactions were recorded. The ones listed here are all rated Moderate: acarbose, doxycycline, hydrocortisone, albiglutide, alogliptin, metformin, pioglitazone, bupropion, triamcinolone, acetylsalicylic acid, dexamethasone, betamethasone, budesonide, acetohexamide, canagliflozin, chenodeoxycholic acid, chlorpropamide, clarithromycin, clotrimazole and dapagliflozin.
Coagulation concern: Asparaginase products are associated with a higher thrombosis risk because of reduced synthesis of coagulation proteins. This is relevant to the other lower-ranked predictions, which involve coagulation disorders.

Please also refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The insomnia prediction rests only on a model score, with no clinical trials, no literature and no plausible mechanistic link. Evidence level is L5.

To proceed, the following is needed:

Any study that directly examines calaspargase pegol in insomnia
Detailed mechanism of action data
Package insert warnings and contraindications from Health Canada
A clear rationale for why a drug for leukemia would treat a sleep disorder, since none is currently apparent
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.